128 related articles for article (PubMed ID: 7664796)
1. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13.
Lebel-Binay S; Laguerre B; Quintin-Colonna F; Conjeaud H; Magazin M; Miloux B; Pecceu F; Caput D; Ferrara P; Fradelizi D
Eur J Immunol; 1995 Aug; 25(8):2340-8. PubMed ID: 7664796
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
[TBL] [Abstract][Full Text] [Related]
4. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.
Pappo I; Tahara H; Robbins PD; Gately MK; Wolf SF; Barnea A; Lotze MT
J Surg Res; 1995 Feb; 58(2):218-26. PubMed ID: 7861776
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
6. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
[TBL] [Abstract][Full Text] [Related]
7. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.
Tahara H; Zitvogel L; Storkus WJ; Zeh HJ; McKinney TG; Schreiber RD; Gubler U; Robbins PD; Lotze MT
J Immunol; 1995 Jun; 154(12):6466-74. PubMed ID: 7759882
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
9. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
[TBL] [Abstract][Full Text] [Related]
10. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
11. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
Sun T; Kim TS; Waltz MR; Cohen EP
Cancer Gene Ther; 1995 Sep; 2(3):183-90. PubMed ID: 8528961
[TBL] [Abstract][Full Text] [Related]
14. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
16. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.
Richter G; Krüger-Krasagakes S; Hein G; Hüls C; Schmitt E; Diamantstein T; Blankenstein T
Cancer Res; 1993 Sep; 53(18):4134-7. PubMed ID: 8364905
[TBL] [Abstract][Full Text] [Related]
18. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo.
Hazama S; Noma T; Wang F; Iizuka N; Ogura Y; Yoshimura K; Inoguchi E; Hakozaki M; Hirose K; Suzuki T; Oka M
Br J Cancer; 1999 Jul; 80(9):1420-6. PubMed ID: 10424745
[TBL] [Abstract][Full Text] [Related]
19. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
Miki S; Ksander B; Streilein JW
Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
[TBL] [Abstract][Full Text] [Related]
20. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
